Pharmacological modifications of dopamine transmission do not influence the striatal in vivo binding of [3H]mazindol or [3H]cocaine in mice

Neuroscience Letters

Volumn 205, Issue 3, 1996, Pages 145-148

  Thibaut, Florence ^a   Bonnet, Jean Jacques ^a   Vaugeois, Jean Marie ^a   Costentin, Jean ^a  

^a U de Neuropsychopharmacologie Exp   (France)

Author keywords

Dexamphetamine; Dopamine transmission; Gammabutyrolactone; In vivo binding; L DOPA; 3H Cocaine; 3H Mazindol

Indexed keywords

COCAINE; DESIPRAMINE; DEXAMPHETAMINE; DOPAMINE TRANSPORTER; GAMMA BUTYROLACTONE; LEVODOPA; MAZINDOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029964710     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3940(96)12399-5     Document Type: Article

References (24)

1. Abercromazie, E.D., Bonatz, A.E. and Zigmond, M.J., Effects of L-DOPA on extracellular DA in striatum of normal and 6-hydroxydopamine-treated rats, Brain Res., 525 (1990) 36-44.
2. 11C]nomifensine and positron emission tomography, Acta Neurol. Scand., 76 (1987) 283-287.
3. 3H]mazindol, J. Pharmacol. Exp. Ther., 253 (1990) 1206-1214.
4. Bonnet, J.-J. and Costentin, J., GBR 12783, a potent and selective inhibitor of dopamine uptake: biochemical studies in vivo and ex vivo, Eur. J. Pharmacol., 121 (1986) 199-209.
5. Cerruti, C., Drian, M.-J., Kamenka, J.-M. and Privat, A., Localization of dopamine carriers by BTCP, a dopamine uptake inhibitor, on nigral cells cultured in vitro, Brain Res., 555 (1991) 51-57.
6. Di Chiara, G. and Imperato, A., Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats, Proc. Natl. Acad. Sci. USA, 85 (1988) 5274-5278.
7. Duterte-Boucher, D., Vaugeois, J.-M., Costentin, J., Ilagouma, A., Maurice, T., Vignon, J. and Kamenka, J.-M., In vivo and in vitro effects of BTCP and derivatives related to dopamine and norepinephrine neuronal uptake inhibition. In J.-M. Kamenka and E.F. Domino (Eds.), Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection, NPP Books, Ann Arbor, 1992, pp. 435-443.
8. Fowler, J.S., Volkow, N.D., Wolf, A.P., Dewey, L., Schlyer, D.J., MacGregor, R.R., Hitzemann, R., Logan, J., Bendriem, B., Gatley, S.J. and Christman, D., Mapping cocaine binding sites in human and baboon brain in vivo, Synapse, 4 (1989) 371-377.
9. 3H]Mazindol binding associated with neuronal dopamine and norepinephrine uptake sites, Mol. Pharmacol., 26 (1984) 35-44.
10. Heal, D.J., Frankland, A.T. and Buckett, W.R., A new and highly sensitive method for measuring 3-methoxytyramine using HPLC with electrochemical detection: studies with drugs which alter dopamine metabolism in the brain, Neuropharmacology, 29 (1990) 1141-1150.
11. 18F] GBR 13119 to the brain dopamine uptake system, Life Sci., 42 (1988) 1347-1353.
12. Kuckzenski, R., Segal, D.S. and Aizenstein, M.L., Amphetamine, cocaine and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics, J. Neurosci., 11 (1989) 2703-2712.
13. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates, Synapse, 13 (1993) 295-309.
14. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J., Protein measurement with the Folin phenol reagent, J. Biol. Chem., 193 (1951) 265-275.
15. Madras, B.K. and Kaufman, M.I., Cocaine accumulates in dopamine rich regions of primate brain after i.v. administration: comparison with mazindol distribution, Synapse, 18 (1994) 261-275.
16. 3H]BTCP, a phencyclidine derivative) binding to the dopamine uptake complex, Neuropharmacology, 30 (1991) 591-598.
17. Nissbrandt, H., Sunström, E., Jonsson, G., Hjorth, S. and Carlsson, A., Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacta, pars reticulata and striatum, J. Neurochem., 52 (1989) 1170-1182.
18. 3H]WIN 35,428 binding to dopamine uptake sites in vivo more rapidly than mazindol or GBR 12909, Eur. J. Pharmacol., 198 (1991) 203-205.
19. Protais, P., Costentin, J. and Schwartz J.-C., Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum, Psychopharmacology, 50 (1976) 1-6.
20. Richelson, E. and Pfenning, M., Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake, Eur. J. Pharmacol., 104 (1984) 277-286.
21. 3H]GBR 12783 binding in vivo, Eur. J. Pharmacol., 178 (1990) 221-227.
22. Volkow, N.D., Fowler, J.S., Logan, J., Gatley, J., Dewey, S.L., MacGregor, R.R., Schyler, D.J., Pappas, N., King, P., Wang, G.-J. and Wolf, A.P., Carbon-11-cocaine binding compared at subpharmacological and pharmacological doses: a PET study, J. Nucl. Med., 36 (1995) 1289-1297.
23. 11C]WIN 35,428, Synapse, 15 (1993) 130-142.
24. Wood, P. and Altar, C.A., Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons: utility of 3-methoxytyramine measurements, Pharmacol. Rev., 40 (1988) 163-187.